semaglutide compounding enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Semaglutide Shortage Ends: Compounded Versions
Description
Retatrutide is in phase 3 clinical trials
The key takeaway is that you control the concentration
adjusted HR, 1.79
As there is no meaningful expression of GLP-1 receptors on hepatocytes, the major effect of GLP-1 agonists on MASH is likely to be indirect and may be related to a reduction in calorie intake, body weight and insulin resistance, all of which would lead to reduced liver lipid accumulation and hepatic inflammation 7,8
As clinicians continue to address the growing overlap between obesity, diabetes, and chronic pain, GLP-1 therapies are attracting attention as a potentially broader metabolic intervention
